Literature DB >> 11316181

Narcotic analgesic effects on the sphincter of Oddi: a review of the data and therapeutic implications in treating pancreatitis.

D R Thompson1.   

Abstract

OBJECTIVE: Traditional teaching dictates that morphine induces "spasm" in the sphincter of Oddi (SO) and should not be used in acute pancreatitis and that meperidine is the analgesic of choice because it does not elevate SO pressures. A literature search and review was performed to evaluate this teaching examining the effect of narcotic analgesic's effects on SO.
METHODS: A Medline search was performed using keywords and phrases. The manufacturers of meperidine were contacted and their reports and studies were obtained and reviewed.
RESULTS: Initial studies measured biliary pressure after narcotic administration in animals, and postoperative and intraoperative cholecystectomy patients. All narcotics increased biliary pressure, but morphine was associated with the largest elevation. Later studies using endoscopic retrograde cholangiopancreatography with direct SO manometry demonstrated that the SO is exquisitely sensitive to all narcotics including meperidine and that a small increase in biliary sphincter pressure is seen with higher doses of morphine. All narcotics increase SO phasic wave frequency and interfere with SO peristalsis.
CONCLUSIONS: Narcotic-induced increases in phasic wave frequency interfere with SO filling and are responsible for the increase in bile duct pressure seen on the initial studies. No studies directly compare the effects of meperidine or morphine on SO manometry and no comparative studies exist in patients with acute pancreatitis. No outcome-based studies comparing these drugs have been performed in patients with acute pancreatitis. Morphine may be of more benefit than meperidine by offering longer pain relief with less risk of seizures. No studies or evidence exist to indicate morphine is contraindicated for use in acute pancreatitis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11316181     DOI: 10.1111/j.1572-0241.2001.03536.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  31 in total

1.  [Acute pancreatitis].

Authors:  N Teich; S Leinung; S Jonas; J Mössner
Journal:  Chirurg       Date:  2009-03       Impact factor: 0.955

Review 2.  The investigation of unexplained biliary dilatation.

Authors:  Alan Coss; Robert Enns
Journal:  Curr Gastroenterol Rep       Date:  2009-04

Review 3.  Acute pancreatitis at the beginning of the 21st century: the state of the art.

Authors:  Alfredo F Tonsi; Matilde Bacchion; Stefano Crippa; Giuseppe Malleo; Claudio Bassi
Journal:  World J Gastroenterol       Date:  2009-06-28       Impact factor: 5.742

Review 4.  Pancreatic Disorders.

Authors:  Aliye Uc; Douglas S Fishman
Journal:  Pediatr Clin North Am       Date:  2017-06       Impact factor: 3.278

5.  Meperidine restriction in a pediatric hospital.

Authors:  Kim W Benner; Spencer H Durham
Journal:  J Pediatr Pharmacol Ther       Date:  2011-07

Review 6.  Treatment with Methylnaltrexone and IVIG for Paraneoplastic Gastrointestinal Dysmotility.

Authors:  Madhusudan Grover; Michael Camilleri
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-01

7.  After distal pancreatectomy pancreatic leakage from the stump of the pancreas may be due to drain failure or pancreatic ductal back pressure.

Authors:  Yasushi Hashimoto; L William Traverso
Journal:  J Gastrointest Surg       Date:  2012-03-06       Impact factor: 3.452

Review 8.  The "Culture" of Pain Control: A Review of Opioid-Induced Dysbiosis (OID) in Antinociceptive Tolerance.

Authors:  Ryan A Mischel; Karan H Muchhala; William L Dewey; Hamid I Akbarali
Journal:  J Pain       Date:  2019-12-11       Impact factor: 5.820

Review 9.  Paediatric pancreatitis.

Authors:  John F Pohl; Aliye Uc
Journal:  Curr Opin Gastroenterol       Date:  2015-09       Impact factor: 3.287

Review 10.  [Gastrointestinal emergencies - acute pancreatitis].

Authors:  G Weitz
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-10-19       Impact factor: 0.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.